Redefining clinical trials: Adopting AI for speed, volume and diversity
IBM Business Partners
MAY 6, 2024
Industry analysts report that dropout rates in phase 3 clinical trials can sometimes reach 20% to 30%. Our analysis of the voluntarily reported Form FDA 1572 BMIS database reveals a potential lack of sustainability in the investigator pool, both in the United States (US) and globally (Exhibit 2).
Let's personalize your content